ATLANTA, GA – – (Newsfile Corp. – January 23, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate Therapeutics” or the “Company”) (NASDAQ: FATE). The lawsuit alleges Fate Therapeutics made materially false and/or misleading statements and/or failed to disclose material adverse facts, including: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement on Fate’s long-term clinical and commercial profitability.
If you bought shares of Fate Therapeutics between April 2, 2020 and January 5, 2023 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/fate-therapeutics/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is March 22, 2023.
Lead Plaintiff Deadline Has Passed
March 22, 2023